Ligand Pharmaceuticals Incorporated
A biopharmaceutical company that licenses drug technologies and collects royalties on medicines its partners develop and sell. Its best-known asset is Captisol, a sugar-based "cage" that wraps around hard-to-dissolve drugs to make them stable and deliverable. Founded in 1987 as Progenx, Inc., it was renamed Ligand Pharmaceuticals in 1989 after the biochemistry term for a molecule that binds to a receptor — a nod to its original focus on receptor biology.
Granted 81.6K · Sold 24.0K
Granted 179.5K · Bought 16.0K
Granted 34.3K · Bought 2.5K · Sold 11.2K
Granted 12.8K · Sold 15.0K
Granted 105.4K · Sold 70.7K
Granted 26.5K · Sold 19.4K
Granted 85.4K · Sold 35.8K
Granted 21.3K · Sold 13.5K
Granted 19.0K · Sold 18.2K
Granted 1.0K
Granted 84.7K · Bought 1.5K · Sold 41.8K
Granted 11.6K
Granted 10.2K · Sold 6.5K
Granted 12.0K · Sold 7.5K
Granted 5.6K
Granted 1.0K
Granted 1.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Higgins John LDirector · 20 transactions | +23.5% | 417.7Kas of Dec 2022 | 81.6K | — | 24.0K |
| Davis Todd CChief Executive Officer, Director · 30 transactions | +292.6% | 199.4K | 179.5K | 16.0K | — |
| Foehr Matthew WFormer Executive Officer · 13 transactions | -2% | 162.2Kas of Nov 2022 | 34.3K | 2.5K | 11.2K |
| Aryeh JasonDirector · 13 transactions | -3.7% | 120.6K | 12.8K | — | 15.0K |
| Korenberg Matthew EPresident & COO · 45 transactions | +28.4% | 51.0Kas of Sep 2024 | 105.4K | — | 70.7K |
| Kozarich John WDirector · 63 transactions | +22.5% | 42.6K | 26.5K | — | 19.4K |
| Reardon AndrewCLO & Secretary · 70 transactions | — | 41.6K | 85.4K | — | 35.8K |
| Sabba Stephen LDirector · 15 transactions | +34.2% | 33.6K | 21.3K | — | 13.5K |
| Lamattina John LDirector · 19 transactions | +22.3% | 31.1K | 19.0K | — | 18.2K |
| Patel SunilFormer Director · 2 transactions | 0% | 28.8Kas of Nov 2022 | 1.0K | — | — |
| Espinoza OctavioChief Financial Officer · 78 transactions | — | 26.7K | 84.7K | 1.5K | 41.8K |
| Berkman Charles SFormer Executive Officer · 9 transactions | -14.6% | 23.8Kas of Nov 2022 | 11.6K | — | — |
| Haas JasonDirector · 9 transactions | — | 11.4K | 10.2K | — | 6.5K |
| Gray Nancy RyanDirector · 10 transactions | +141.2% | 8.9K | 12.0K | — | 7.5K |
| Zimmermann MartineDirector · 7 transactions | — | 5.1K | 5.6K | — | — |
| Boyce SarahFormer Director · 2 transactions | 0% | 2.9Kas of Nov 2022 | 1.0K | — | — |
| Cochran Jennifer R.Former Director · 2 transactions | 0% | 1.2Kas of Nov 2022 | 1.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -243.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.